Michael K.K. Wong, PhD, MD, on Early Results on Navtemadlin, a Novel MDM2 Inhibitor, for Merkel Cell Carcinoma

Posted: Friday, March 31, 2023

Michael K.K. Wong, PhD, MD, of The University of Texas MD Anderson Cancer Center, discusses navtemadlin, the first targeted agent to show activity in heavily pretreated patients with Merkel cell carcinoma, for whom anti–PD-1/PD-L1 therapy was not effective. The data seem to indicate that upregulation of the p53 pathway is a viable therapeutic strategy for this aggressive skin cancer with a high risk of recurrence and metastases.

---